Valneva SE

VALN

{{popupValue}}
{{popupSubtitle}}

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
VALN
CIK0001836564
SIC2836
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupBiological Products, Except Diagnostic Substances

Contact

Address6, RUE ALAIN BOMBARD, SAINT-HERBLAIN, I0, 44800
Website valneva.com
Phone33 2 28 07 37 10
CEOThomas Lingelbach
Employees700

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$204.98 million
Pre-Tax Income$-133.93 million
Net Income$-135.19 million
Net Income to Common$-135.19 million
EPS$-0.80
View All
Balance Sheet
Cash$128.69 million
Assets$468.07 million
Liabilities$343.48 million
Common Equity$128.33 million
Liabilities & Equity$321.30 million
View All
Cash Flow Statement
Net Income$-135.19 million
Cash From Operating Activities$-197.93 million
Cash From Investing Activities$-5.19 million
Cash From Financing Activities$-201.43 million
Change in Cash$-404.54 million
View All
Calculations
NOPAT$-67.41 million
EBITDA$-87.86 million
Price to EarningsN/A
Price to Book$6.60
ROEN/A
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Will Pfizer’s Lyme disease gamble pay off or set the space back?

As the disease spreads into new regions, the urgency for prevention is growing.

Article Link

Pfizer (PFE) – Among the 15 Large Cap Stocks with Highest Dividends

Pfizer Inc. (NYSE:PFE) is included among the 15 Large Cap Stocks with Highest Dividends. Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company’s global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer health care products. Pfizer Inc. (NYSE:PFE) […]

Article Link

Should Pfizer’s (PFE) New Lyme Vaccine and Oncology Wins Reshape Its Post‑COVID Pipeline Story?

In March 2026, Pfizer and partner Valneva reported that their investigational 6‑valent OspA-based Lyme disease vaccine achieved roughly three‑quarters efficacy in a Phase 3 trial, while separate late‑stage studies in prostate and breast cancer also met key endpoints with TALZENNA and atirmociclib. Together, these trial wins highlight how Pfizer’s late‑stage pipeline is broadening beyond COVID-era products into vaccines and oncology programs that could reshape its future product mix. We’ll...

Article Link

Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data

Pfizer Inc. (NYSE:PFE) is included among the Dividend Stock Portfolio for Income: 15 Stocks to Invest In. On March 24, Guggenheim Partners raised its price recommendation on Pfizer Inc. (NYSE:PFE) to $36 from $35. It reiterated a Buy rating on the shares. The analyst pointed to upcoming data from the MEVPRO-1 Phase 3 trial of […]

Article Link

Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC

Lyon (France), March 26, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its participation in the upcoming 26th World Vaccine Congress, which will take place from March 31 to April 2, 2026 at the Walter E. convention center in Washington, D.C. Led by the Company´s Chief Executive Officer, Thomas Lingelbach, a team of Valneva´s senior executives will participate in multiple events throughout the conference. On April 1, 2026, at 9:40 am EST, Susa

Article Link